AstraZeneca Annual Report and Form 20-F Information 2011
AstraZeneca Annual Report and Form 20-F Information 2011
AstraZeneca Annual Report and Form 20-F Information 2011
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Financial Statements10 Other investments<strong>20</strong>11$m<strong>20</strong>10$m<strong>20</strong>09$mNon-current investmentsEquity securities available for sale <strong>20</strong>1 211 184<strong>20</strong>1 211 184Current investmentsEquity securities <strong>and</strong> bonds available for sale 296 355 –Equity securities held for trading 25 <strong>20</strong> 18Fixed deposits 3,927 1,107 1,4664,248 1,482 1,484The equity securities <strong>and</strong> bonds available for sale in current investments of $296m (<strong>20</strong>10: $355m; <strong>20</strong>09: $nil) are held in an escrow account.Further details of this escrow account are included in Note 18.Fixed deposits relate to investments in US Treasury bills <strong>and</strong> commercial paper with a maturity of greater than 90 days at inception.Impairment charges of $3m in respect of available for sale securities are included in other operating income <strong>and</strong> expense in profit(<strong>20</strong>10: $2m; <strong>20</strong>09: $18m).11 InventoriesRaw materials <strong>and</strong> consumables 588 539 445Inventories in process 645 665 726Finished goods <strong>and</strong> goods for resale 619 478 5791,852 1,682 1,750<strong>20</strong>11$m<strong>20</strong>10$m<strong>20</strong>09$mInventory write-offs in the year amounted to $51m (<strong>20</strong>10: $69m; <strong>20</strong>09: $83m).12 Trade <strong>and</strong> other receivables<strong>20</strong>11$m<strong>20</strong>10$m<strong>20</strong>09$mAmounts due within one yearTrade receivables 6,696 6,328 5,863Less: Amounts provided for doubtful debts (Note 23) (66) (81) (81)6,630 6,247 5,782Other receivables 1,172 607 1,170Prepayments <strong>and</strong> accrued income 725 733 5808,527 7,587 7,532Amounts due after more than one yearOther receivables 65 64 27Prepayments <strong>and</strong> accrued income 162 196 150227 260 177Trade <strong>and</strong> other receivables 8,754 7,847 7,70913 Cash <strong>and</strong> cash equivalentsCash at bank <strong>and</strong> in h<strong>and</strong> 1,488 1,750 1,077Short-term deposits 6,083 9,318 8,841Cash <strong>and</strong> cash equivalents 7,571 11,068 9,918Unsecured bank overdrafts (137) (87) (90)Cash <strong>and</strong> cash equivalents in the cash flow statement 7,434 10,981 9,828<strong>20</strong>11$m<strong>20</strong>10$m<strong>20</strong>09$mThe Group’s insurance subsidiaries hold cash <strong>and</strong> cash equivalents totalling $776m (<strong>20</strong>10: $415m; <strong>20</strong>09: $173m), of which $543m (<strong>20</strong>10: $370m;<strong>20</strong>09: $49m) is required to meet insurance solvency requirements <strong>and</strong> which, as a result, is not readily available for the general purposes ofthe Group.160 Financial Statements<strong>AstraZeneca</strong> <strong>Annual</strong> <strong>Report</strong> <strong>and</strong> <strong>Form</strong> <strong>20</strong>-F <strong>Information</strong> <strong>20</strong>11
Change language